Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Omalizumab
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Xolair
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 06, 2020
Details:
EC approves Xolair® (omalizumab) as an add-on therapy for severe chronic rhinosinusitis with nasal polyps, the first anti-immunoglobulin E antibody approved in this indication.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Fluticasone
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Xhance
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Optinose
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 08, 2020
Details:
Under the terms of the agreement, kaléo will promote XHANCE to an agreed-upon audience of office-based healthcare professionals, rapidly increasing promotional reach and frequency.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ciprofloxacin
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Otiprio
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Otonomy
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 17, 2020
Details:
Under the terms of the agreement, ALK will have exclusive rights to promote OTIPRIO for AOE to office-based healthcare professionals in the U.S. including ENT physicians, pediatricians and select primary care physicians.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
